<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293926</url>
  </required_header>
  <id_info>
    <org_study_id>UEM50</org_study_id>
    <nct_id>NCT04293926</nct_id>
  </id_info>
  <brief_title>Heart Rate Variability in Children and Adolescents With Cystic Fibrosis</brief_title>
  <official_title>Effects of a Resistance Training Program on Heart Rate Variability in Children and Adolescents With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Europea de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Europea de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effects of a resistance exercise training program on heart rate&#xD;
      variability in a group of children and adolescents with cystic fibrosis. The study design is&#xD;
      a randomized controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled study will be carried out in children diagnosed with cystic fibrosis&#xD;
      aged 6 to 18 years. Individuals will be divided into two groups: control group (CON) and&#xD;
      strength training (ST). Heart rate variability will be analyzed using KUBIOS and measured&#xD;
      using a Suunto watch, with subjects in lying position without movements or speaking for 5&#xD;
      minutes. Patients in the ST group will complete an individualized guided strength program for&#xD;
      8 weeks (3 sessions of 60 min/week). Training prescription will be individualized and based&#xD;
      on the 5 repetition maximum test (60-80%). Upper and lower limbs exercises will be used,&#xD;
      including seated bench press, seated lateral row and leg press. Outcome measures will be&#xD;
      performed at baseline and after 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2020</start_date>
  <completion_date type="Actual">September 7, 2020</completion_date>
  <primary_completion_date type="Actual">September 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the standard deviation of R-R intervals (SDNN) expressed in milliseconds (m/s)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in time-domain SDNN will be measured through heart rate variability assessment using a heart rate band and an Ambit 3 Sport watch. Variables will be collected during a five minute period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the root mean square standard deviation (RMSSD) expressed in milliseconds (m/s)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in time-domain RMSSD will be measured through heart rate variability assessment using a heart rate band and an Ambit 3 Sport watch. Variables will be collected during a five minute period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the percentage of differences between R-R intervals higher than 50 m/s (PNN50) expressed in percentage (%)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in time-domain PNN50 will be measured through heart rate variability assessment using a heart rate band and an Ambit 3 Sport watch. Variables will be collected during a five minute period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the low frequency band (LF) expressed in normalized unites (nu)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in frequency-domain LF will be measured through heart rate variability assessment using a heart rate band and an Ambit 3 Sport watch. Variables will be collected during a five minute period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the high frequency band (HF) expressed in normalized unites (nu)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in frequency-domain HF will be measured through heart rate variability assessment using a heart rate band and an Ambit 3 Sport watch. Variables will be collected during a five minute period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the quotient (LF/HF) between the low frequency band (LF) and the high frequency band (HF) expressed as a ratio</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in frequency-domain HF will be measured through heart rate variability assessment using a heart rate band and an Ambit 3 Sport watch. Variables will be collected during a five minute period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the forced expiratory volume in one second (FEV1) expressed as z-score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in FEV1 will be measured using spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the forced vital capacity (FVC) expressed as z-score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Changes in FVC will be measured using spirometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cystic Fibrosis in Children</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will receive routine recommendations by the pediatrician, including specific lifestyle advises.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive routine recommendations by the pediatrician, including specific lifestyle advises. In addition, a 8-week resistance exercise training program will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Cystic Fibrosis&#xD;
&#xD;
          -  Age between 6 and 18 years old&#xD;
&#xD;
          -  Mild to moderate lung function levels&#xD;
&#xD;
          -  Signature of the informed consent form by legal guardian and patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  Exacerbation in the last 3 months&#xD;
&#xD;
          -  Presence of gastrostomy&#xD;
&#xD;
          -  Use of beta-blocker drugs&#xD;
&#xD;
          -  Diagnosed heart disease&#xD;
&#xD;
          -  Alterations in the locomotor system&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margarita Perez Ruiz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Europea de Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Escuela de Doctorado e Investigacion, Universidad Europea</name>
      <address>
        <city>Villaviciosa De Od√≥n</city>
        <state>Madrid</state>
        <zip>28670</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Europea de Madrid</investigator_affiliation>
    <investigator_full_name>Margarita Perez</investigator_full_name>
    <investigator_title>Full Professor In Exercise Physiology, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Heart Rate Variability</keyword>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

